المؤلفون: Calvanese AL; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Cecconi V; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Stäheli S; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Schnepf D; Institute of Virology, Medical Center University of Freiburg, Freiburg im Breisgau, Germany., Nater M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Pereira P; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Gschwend J; Institute of Physiology, University of Zurich, Zurich, Switzerland., Heikenwälder M; Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.; M3 Research Institute, Eberhard Karls University Tübingen, Tübingen, Germany., Schneider C; Institute of Physiology, University of Zurich, Zurich, Switzerland., Ludewig B; Institute of Immunobiology, Medical Research Center, Kantonsspital St. Gallen, St. Gallen, Switzerland., Silina K; Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., van den Broek M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

المصدر: European journal of immunology [Eur J Immunol] 2024 Jul 09, pp. e2451207. Date of Electronic Publication: 2024 Jul 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 1273201 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-4141 (Electronic) Linking ISSN: 00142980 NLM ISO Abbreviation: Eur J Immunol Subsets: MEDLINE

المؤلفون: Sato Y; Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Silina K; Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., van den Broek M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Hirahara K; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.; Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan., Yanagita M; Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. motoy@kuhp.kyoto-u.ac.jp.; Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan. motoy@kuhp.kyoto-u.ac.jp.

المصدر: Nature reviews. Nephrology [Nat Rev Nephrol] 2023 Aug; Vol. 19 (8), pp. 525-537. Date of Electronic Publication: 2023 Apr 12.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500081 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-507X (Electronic) Linking ISSN: 17595061 NLM ISO Abbreviation: Nat Rev Nephrol Subsets: MEDLINE

مواضيع طبية MeSH: Tertiary Lymphoid Structures*/genetics , Tertiary Lymphoid Structures*/pathology , Neoplasms* , Renal Insufficiency, Chronic*, Humans ; Disease Progression ; Chronic Disease

المؤلفون: van Rijthoven M; Pathology Department, Radboud University Medical Center, Nijmegen, Netherlands. mart.vanrijthoven@radboudumc.nl., Obahor S; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Pagliarulo F; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., van den Broek M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Schraml P; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland., Moch H; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.; Faculty of Medicine, University of Zurich, Zurich, Switzerland., van der Laak J; Pathology Department, Radboud University Medical Center, Nijmegen, Netherlands., Ciompi F; Pathology Department, Radboud University Medical Center, Nijmegen, Netherlands., Silina K; Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland.

المصدر: Communications medicine [Commun Med (Lond)] 2024 Jan 05; Vol. 4 (1), pp. 5. Date of Electronic Publication: 2024 Jan 05.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) Subsets: PubMed not MEDLINE

المؤلفون: Laure, A., Silina, K., Kirschner, M., Opitz, I., Hiltbrunner, S., Curioni-Fontecedro, A.

المصدر: In Immuno-Oncology and Technology December 2022 16 Supplement 1

المؤلفون: Silina K; Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich), Zurich, Switzerland. Electronic address: karina.silina@pharma.ethz.ch.

المصدر: Cancer cell [Cancer Cell] 2023 May 08; Vol. 41 (5), pp. 824-825.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Comment

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

مواضيع طبية MeSH: CD8-Positive T-Lymphocytes* , Neoplasms*/therapy, Humans ; Tumor Microenvironment ; T-Lymphocytes, Cytotoxic ; Antibodies ; B-Lymphocytes

المؤلفون: Sobottka B; Department of Pathology and Molecular Pathology, University of Zurich and University Hospital Zurich., Lorch A; Department of Medical Oncology and Haematology, University Hospital Zurich., Silina K; Institute of Experimental Immunology, University of Zurich.; Comprehensive Cancer Center Zurich, Zurich, Switzerland., van den Broek M; Institute of Experimental Immunology, University of Zurich.; Comprehensive Cancer Center Zurich, Zurich, Switzerland., Moch H; Department of Pathology and Molecular Pathology, University of Zurich and University Hospital Zurich.; Comprehensive Cancer Center Zurich, Zurich, Switzerland.

المصدر: Current opinion in urology [Curr Opin Urol] 2021 May 01; Vol. 31 (3), pp. 228-235.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9200621 Publication Model: Print Cited Medium: Internet ISSN: 1473-6586 (Electronic) Linking ISSN: 09630643 NLM ISO Abbreviation: Curr Opin Urol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell* , Kidney Neoplasms*/therapy, Biomarkers, Tumor ; Humans ; Prognosis ; Tumor Microenvironment

المؤلفون: van Dijk N; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Gil-Jimenez A; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Silina K; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Hendricksen K; Department of Urology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Smit LA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., de Feijter JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Montfoort ML; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Rooijen C; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Peters D; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Poel HG; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Bruining A; Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Lubeck Y; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Sikorska K; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Boellaard TN; Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kvistborg P; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Vis DJ; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Hooijberg E; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Schumacher TN; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van den Broek M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Wessels LFA; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Rhijn BW; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany., van der Heijden MS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. ms.vd.heijden@nki.nl.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands. ms.vd.heijden@nki.nl.

المصدر: Nature medicine [Nat Med] 2020 Dec; Vol. 26 (12), pp. 1839-1844. Date of Electronic Publication: 2020 Oct 12.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

مواضيع طبية MeSH: Ipilimumab/*administration & dosage , Neoplasms/*drug therapy , Nivolumab/*administration & dosage , Urothelium/*pathology, Adult ; Aged ; Antibodies, Monoclonal ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Neoplasms/immunology ; Neoplasms/pathology ; Neoplasms/surgery ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Urothelium/drug effects ; Urothelium/immunology ; Urothelium/surgery

المؤلفون: Silina, K. Soltermann, A. Attar, F.M. Casanova, R. Uckeley, Z.M. Thut, H. Wandres, M. Isajevs, S. Cheng, P. Curioni-Fontecedro, A. Foukas, P. Levesque, M.P. Moch, H. Line, A. Van Den Broek, M.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______2127::403dbece3eac5e5ed57c65e9ec9289c4
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3085555

المؤلفون: Pagliarulo F; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Cheng PF; Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Brugger L; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., van Dijk N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., van den Heijden M; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Levesque MP; Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Silina K; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., van den Broek M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

المصدر: Frontiers in immunology [Front Immunol] 2022 Jan 25; Vol. 12, pp. 793992. Date of Electronic Publication: 2022 Jan 25 (Print Publication: 2021).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Lymphatic Vessels/*metabolism , Lymphatic Vessels/*pathology , Muscles/*pathology , Neovascularization, Pathologic/*etiology , Neovascularization, Pathologic/*metabolism , Urinary Bladder Neoplasms/*pathology, Biomarkers ; Biomarkers, Tumor ; Diagnostic Imaging ; Disease Susceptibility ; Fluorescent Antibody Technique ; Gene Expression Profiling ; Gene Expression Regulation ; Humans ; Kaplan-Meier Estimate ; Lymphocytes, Tumor-Infiltrating ; Microvascular Density ; Neoplasm Invasiveness ; Neoplasm Staging ; Neovascularization, Pathologic/diagnostic imaging ; Prognosis ; Tumor Microenvironment ; Urinary Bladder Neoplasms/etiology ; Urinary Bladder Neoplasms/metabolism ; Urinary Bladder Neoplasms/mortality

المؤلفون: van Dijk N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Gil-Jimenez A; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Silina K; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., van Montfoort ML; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Einerhand S; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Jonkman L; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, Netherlands., Voskuilen CS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Peters D; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, Netherlands., Sanders J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Lubeck Y; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, Netherlands., Hooijberg E; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Vis DJ; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., van den Broek M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Wessels LFA; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands.; Department of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, Netherlands., van Rhijn BWG; Department of Urology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany., van der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.

المصدر: Frontiers in immunology [Front Immunol] 2021 Dec 20; Vol. 12, pp. 793964. Date of Electronic Publication: 2021 Dec 20 (Print Publication: 2021).

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: CD8-Positive T-Lymphocytes/*immunology , Immune Checkpoint Inhibitors/*therapeutic use , Ipilimumab/*therapeutic use , Nivolumab/*therapeutic use , T-Lymphocytes, Helper-Inducer/*immunology , Urothelium/*metabolism, Aged ; CTLA-4 Antigen/antagonists & inhibitors ; Cell Differentiation ; Cells, Cultured ; Female ; Fluorescent Antibody Technique ; Forkhead Transcription Factors/metabolism ; Humans ; Immunotherapy ; Lymphocyte Activation ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; Tertiary Lymphoid Structures ; Treatment Outcome ; Tumor Microenvironment ; Urologic Neoplasms ; Urothelium/pathology